Dr. Novack’s paper among top 100 glaucoma papers

The American Glaucoma Society recently sought to identify 100 articles with significant impact on the clinical care of patients with glaucoma. This was based upon citation frequency and the input of members of the Society. The results of this activity was recently published by Drs. Vinod, Gedde and Ramulu in Ophthalmology Glaucoma. One of Dr. Novack’s papers on a new class of topical ocular hypotensive agents was selected (Serle JB et al. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-27).

About Dr. Novack

Dr. Gary Novack is a board-certified clinical pharmacologist and President of PharmaLogic Development with more than 40 years of experience in ophthalmic drug development, clinical research, and FDA regulatory strategy.

He has consulted for over 100 pharmaceutical and medical device companies and authored more than 400 scientific publications.

Contact Dr. Novack
Contact Dr. Novack